Ultra-fast proton radiation plus tiny immune-drug implants for pancreatic cancer
Project #2
Combining very-fast proton radiation with smart implants that slowly release immunotherapy to better kill pancreatic tumors while protecting nearby organs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Howard University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11196091 on NIH RePORTER |
What this research studies
This project develops a combined treatment that uses FLASH proton radiation—an ultra-high dose delivered in a very short time—together with small biomaterial implants that slowly release immune-boosting drugs near the tumor. Researchers will optimize how to deliver the radiation and the timing and dosing of the implanted therapy, and gather safety and drug-distribution data. Studies will include laboratory and animal work to measure tumor response, effects on nearby stomach and bowel, and immune changes that might also shrink distant metastases. The team aims to produce the data needed to move this approach toward future clinical trials in people.
Who could benefit from this research
Good fit: Ideal candidates would be people with localized or locally advanced pancreatic cancer who are seeking new treatment options and could tolerate a radiation procedure and implant placement.
Not a fit: People with widespread metastatic disease unlikely to be helped by a local radiation-and-implant approach, or those unable to undergo radiation or minor surgical procedures, may not benefit.
Why it matters
Potential benefit: If successful, this approach could let doctors use much stronger, tumor-killing radiation for pancreatic cancer with fewer side effects and better immune-driven control of metastases.
How similar studies have performed: Early preclinical FLASH radiation studies show reduced normal tissue damage and promising immune effects, but combining FLASH proton therapy with sustained-release biomaterials for immunotherapy is relatively new and not yet proven in humans.
Where this research is happening
Washington, United States
- Howard University — Washington, United States (Active)
Researchers
- Principal investigator: Hudson, Tamaro Syton — Howard University
- Study coordinator: Hudson, Tamaro Syton
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.